Literature DB >> 23218560

Characterizing trajectories of cognitive functioning in older adults with schizophrenia: does method matter?

Wesley K Thompson1, Gauri N Savla, Ipsit V Vahia, Colin A Depp, Ruth O'Hara, Dilip V Jeste, Barton W Palmer.   

Abstract

BACKGROUND: Heterogeneity in clinical outcomes may be caused by factors working at multiple levels, e.g., between groups, between subjects, or within subjects over time. A more nuanced assessment of differences in variation among schizophrenia patients and between patients and healthy comparison subjects can clarify etiology and even facilitate the identification of patient subtypes with common neuropathology and clinical course.
METHODS: We compared trajectories (mean duration of 3.5years) of cognitive impairments in a sample of 201 community-dwelling schizophrenia (SCZ) patients (aged 40-100years) with 67 healthy comparison (HC) subjects. We employed growth mixture models to discover subclasses with more homogenous between-subject variation in cognitive trajectories. Post hoc analyses determined factors associated with class membership and class-specific correlates of cognitive trajectories.
RESULTS: Three latent classes were indicated: Class 1 (85% HC and 50% SCZ) exhibited relatively high and stable trajectories of cognition, Class 2 (15% HC and 40% SCZ) exhibited lower, modestly declining trajectories, and Class 3 (10% SCZ) exhibited lower, more rapidly declining trajectories. Within the patient group, membership in Classes 2-3 was associated with worse negative symptoms and living in a board and care facility. DISCUSSION: These results bridge the gap between schizophrenia studies demonstrating cognitive decline and those demonstrating stability. Moreover, a finer-grained characterization of heterogeneity in cognitive trajectories has practical implications for interventions and for case management of patients who show accelerated cognitive decline. Such a characterization requires study designs and analyses sensitive to between- and within-patient heterogeneity in outcomes.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23218560      PMCID: PMC3540183          DOI: 10.1016/j.schres.2012.10.033

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  33 in total

1.  How can we learn about developmental processes from cross-sectional studies, or can we?

Authors:  H C Kraemer; J A Yesavage; J L Taylor; D Kupfer
Journal:  Am J Psychiatry       Date:  2000-02       Impact factor: 18.112

2.  A comparison of community-dwelling older schizophrenia patients by residential status.

Authors:  L A Auslander; L L Lindamer; J Delapena; K Harless; D Polichar; T L Patterson; S Zisook; D V Jeste
Journal:  Acta Psychiatr Scand       Date:  2001-05       Impact factor: 6.392

3.  Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients.

Authors:  P D Harvey; J M Silverman; R C Mohs; M Parrella; L White; P Powchik; M Davidson; K L Davis
Journal:  Biol Psychiatry       Date:  1999-01-01       Impact factor: 13.382

Review 4.  Subtyping schizophrenia: implications for genetic research.

Authors:  A Jablensky
Journal:  Mol Psychiatry       Date:  2006-06-27       Impact factor: 15.992

Review 5.  Cognitive impairment in elderly patients with schizophrenia: age related changes.

Authors:  P D Harvey
Journal:  Int J Geriatr Psychiatry       Date:  2001-12       Impact factor: 3.485

6.  Stability and course of neuropsychological deficits in schizophrenia.

Authors:  R K Heaton; J A Gladsjo; B W Palmer; J Kuck; T D Marcotte; D V Jeste
Journal:  Arch Gen Psychiatry       Date:  2001-01

Review 7.  Is schizophrenia a syndrome of accelerated aging?

Authors:  Brian Kirkpatrick; Erick Messias; Philip D Harvey; Emilio Fernandez-Egea; Christopher R Bowie
Journal:  Schizophr Bull       Date:  2007-12-21       Impact factor: 9.306

8.  The psychiatric symptomatology of deficit schizophrenia: a meta-analysis.

Authors:  Alex S Cohen; Laura A Brown; Kyle S Minor
Journal:  Schizophr Res       Date:  2009-11-03       Impact factor: 4.939

9.  Premorbid IQ in schizophrenia: a meta-analytic review.

Authors:  Kristen A Woodberry; Anthony J Giuliano; Larry J Seidman
Journal:  Am J Psychiatry       Date:  2008-04-15       Impact factor: 18.112

Review 10.  Longitudinal studies of cognition in schizophrenia: meta-analysis.

Authors:  Andrei Szöke; Anca Trandafir; Marie-Estelle Dupont; Alexandre Méary; Franck Schürhoff; Marion Leboyer
Journal:  Br J Psychiatry       Date:  2008-04       Impact factor: 9.319

View more
  12 in total

1.  Thought, language, and communication deficits and association with everyday functional outcomes among community-dwelling middle-aged and older adults with schizophrenia.

Authors:  Anjana Muralidharan; Anastasia Finch; Christopher R Bowie; Philip D Harvey
Journal:  Schizophr Res       Date:  2017-08-01       Impact factor: 4.939

2.  Assessment of 3-dimensional wisdom in schizophrenia: Associations with neuropsychological functions and physical and mental health.

Authors:  Ryan Van Patten; Ellen E Lee; Rebecca Daly; Elizabeth Twamley; Xin M Tu; Dilip V Jeste
Journal:  Schizophr Res       Date:  2019-02-14       Impact factor: 4.939

3.  Promoting Personal and Social Recovery in Older Persons with Schizophrenia: The Case of The New Club, a Novel Dutch Facility Offering Social Contact and Activities.

Authors:  Paul D Meesters; Lia van der Ham; Marcia Dominicus; Max L Stek; Tineke A Abma
Journal:  Community Ment Health J       Date:  2019-03-15

4.  Nonsocial and social cognition in schizophrenia: current evidence and future directions.

Authors:  Michael F Green; William P Horan; Junghee Lee
Journal:  World Psychiatry       Date:  2019-06       Impact factor: 49.548

5.  DNA methylation in the human frontal cortex reveals a putative mechanism for age-by-disease interactions.

Authors:  Brandon C McKinney; Chien-Wei Lin; Tanbin Rahman; Hyunjung Oh; David A Lewis; George Tseng; Etienne Sibille
Journal:  Transl Psychiatry       Date:  2019-01-29       Impact factor: 6.222

Review 6.  Cognitive impairment in psychotic illness: prevalence, profile of impairment, developmental course, and treatment considerations
.

Authors:  Amanda McCleery; Keith H Nuechterlein
Journal:  Dialogues Clin Neurosci       Date:  2019-09       Impact factor: 5.986

7.  Variations in Dysbindin-1 are associated with cognitive response to antipsychotic drug treatment.

Authors:  Diego Scheggia; Rosa Mastrogiacomo; Maddalena Mereu; Sara Sannino; Richard E Straub; Marco Armando; Francesca Managò; Simone Guadagna; Fabrizio Piras; Fengyu Zhang; Joel E Kleinman; Thomas M Hyde; Sanne S Kaalund; Maria Pontillo; Genny Orso; Carlo Caltagirone; Emiliana Borrelli; Maria A De Luca; Stefano Vicari; Daniel R Weinberger; Gianfranco Spalletta; Francesco Papaleo
Journal:  Nat Commun       Date:  2018-06-11       Impact factor: 14.919

Review 8.  A systematic review and narrative synthesis of data-driven studies in schizophrenia symptoms and cognitive deficits.

Authors:  Tesfa Dejenie Habtewold; Lyan H Rodijk; Edith J Liemburg; Grigory Sidorenkov; H Marike Boezen; Richard Bruggeman; Behrooz Z Alizadeh
Journal:  Transl Psychiatry       Date:  2020-07-21       Impact factor: 6.222

9.  Long-term cognitive trajectories and heterogeneity in patients with schizophrenia and their unaffected siblings.

Authors:  Md A Islam; T D Habtewold; F D van Es; P J Quee; E R van den Heuvel; B Z Alizadeh; R Bruggeman
Journal:  Acta Psychiatr Scand       Date:  2018-09-21       Impact factor: 6.392

10.  Construct Validity of the Mentalization Scale (MentS) Within a Mixed Psychiatric Sample.

Authors:  Felix Richter; Dagmar Steinmair; Henriette Löffler-Stastka
Journal:  Front Psychol       Date:  2021-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.